








Exzitation versus Inhibition


























Intracranial structural asym Predictors for structural asymmetric asymmetrical seizure episodes, a sy interictal neurological examination	cal lesions include	age of	f seizure on ictal neurolo	iset >6years, the c gical examination a	occurrence of cl nd an asymmetr	uster seizures, ically abnormal	THANKET LEFT
Variable	Maximum Odds ratio		SE	95% CI	t Value	P-Value	
Seizure onset >6years	17.81	±	0.28	9.80-32.39	10.21	<0.0001	
Cluster seizure	2.44	±	0.26	1.41-4.21	3.45	0.003	
Asymmetrical seizure	3.23	±	0.39	1.41-7.36	3.01	0.008	
Neuro exam abnormal symmetrical	9.50	±	0.31	4.94-18.28	7.30	<0.0001	
Neuro exam abnormal asymmetrical	27.97	±	0.35	13.38-58.50	9.57	<0.0001	
Intracranial structural symmetrical structural variable			ure onset an SE	d an abnormal symn 95% Cl	netrical neurologi t Value	c examination. <i>P</i> -Value	
Predictors for a symmetrical structura	al lesions are the age Maximum Odds				<i>t</i> Value 2.69	<i>P</i> -Value 0.008	
Predictors for a symmetrical structure Variable	al lesions are the age Maximum Odds ratio	e of seiz	SE	95% CI	t Value	P-Value	
Predictors for a symmetrical structura Variable Age of seizure onset Neuro exam abnormal symmetrical Intracranial functional intracranial Predictors for functional intracranial and normal interictal neurological e lesion with a sensitivity of 82.1% and	Al lesions are the age Maximum Odds ratio 1.06 6.06 ons esions are: age of s xamination Combin a specificity of 83.9	± ± ± seizure <	SE 0.02 0.64	95% Cl 1.01-1.10 1.71-21.44 urrence of a single a n predict the preser	t Value 2.69 2.81 nd symmetrical s	P-Value 0.008 0.05 seizure episode nal intracranial	
Predictors for a symmetrical structura Variable Age of seizure onset Neuro exam abnormal symmetrical Intracranial functional intracranial Predictors for functional intracranial and normal interictal neurological e lesion with a sensitivity of 82.1% and Variable	Al lesions are the age Maximum Odds ratio 1.06 6.06 esions are: age of s xamination Combin a specificity of 83.9 Maximum Odds ratio	± ± ± seizure < ed, these %.	SE 0.02 0.64 66years, occu e factors ca SE	95% Cl 1.01-1.10 1.71-21.44 urrence of a single a n predict the present 95% Cl	t Value 2.69 2.81 nd symmetrical s nce on a function t Value	P-Value 0.008 0.05 elizure episode nal intracranial P-Value	
Predictors for a symmetrical structura Variable Age of seizure onset Neuro exam abnormal symmetrical Intracranial functional lessio Predictors for functional intracranial and normal interictal neurological e lesion with a sensitivity of 82.1% and Variable Seizure onset <6years	Maximum Odds ratio 1.06 6.06 esions are: age of s xamination Combin a specificity of 83.9 Maximum Odds ratio 13.55	± ± ± seizure <	SE 0.02 0.64 66years, occu e factors ca SE 0.28	95% Cl 1.01-1.10 1.71-21.44 urrence of a single a n predict the preser 95% Cl 7.47-24.58	t Value 2.69 2.81 nd symmetrical s nee on a function t Value 9.75	P-Value 0.008 0.05 eizure episode nal intracranial P-Value <0.0001	
Predictors for a symmetrical structura Variable Age of seizure onset Neuro exam abnormal symmetrical Intracranial functional intracranial Predictors for functional intracranial and normal interictal neurological e lesion with a sensitivity of 82.1% and Variable	Al lesions are the age Maximum Odds ratio 1.06 6.06 esions are: age of s xamination Combin a specificity of 83.9 Maximum Odds ratio	± ± ± seizure < ed, these %.	SE 0.02 0.64 66years, occu e factors ca SE	95% Cl 1.01-1.10 1.71-21.44 urrence of a single a n predict the present 95% Cl	t Value 2.69 2.81 nd symmetrical s nce on a function t Value	P-Value 0.008 0.05 elizure episode nal intracranial P-Value	












Diseases to	be considered in cats present	ing with seizures	CITE HOCH
Category	Subcategory	Possible aetiologies	Interictal neurological deficits possible? Progressive? Symmetrical/Asymmetrical
Idiopathic	Genetic?	- / Gene defect (susceptibility/causative)	-
Structural	Degenerative	Hippocampal necrosis* Storage diseases	- Yes & Progressive & Symmetrical
	Anomalous	Hydrocephalus Lissencephaly	Yes & Progressive & Symmetrical Yes & Progressive & Asymmetrical
	Neoplastic	Primary (e.g. Meningioma, glioma [rare], lymphoma [rare]) Secondary/metastatic (e.g. lymphoma)	Yes & Progressive & Asymmetrical
	Inflammatory	VGKC-associated limbic encephalitis	- / can have behaviour changes
		Meningoencephalitis of unknown aetiology	Yes & Progressive & Asymmetrical
	Infectious	<i>Toxoplasma gondii</i> Feline immunodeficiency virus Feline infectious peritonitis Rabies Fungal infections	Yes & Progressive & Asymmetrical
	Traumatic	Trauma	Yes & Static/Improving & Asymmetrical






































Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label	Journal of Patine Medicine and Surgery 2017, Vol. 18(2) 200-206 © The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.n DOI: 10.1177/1096812X15622806 (Ims.com)	Table 1 Baseline characteristics of cats allocated to each treatment group					
study	\$SAGE			Levetiracetam (n :	= 34) Pheno	obarbital (n = 34)	Ρ
Mark Lowrie ^{1*} , Sarah Thomson ¹ , Claire Bessant ² , Andrew Sparkes ² , Robert J Harvey ³ and Laurent Garosi ¹		Age (years) Weight (kg) Breed (n) DSH DLH Birman Other Sex (n) F FN M		18 (12-23) 4 (2-8) 17 2 8 7 17 13 17	19 (13 4 (1- 19 1 9 5 15 9 19		0.0 0.2 0.5
Table 3 Efficacy of leveliracetam a	nd phenobarbital in the	MN Age at onset of seizures (years) Time from first seizure to study sta e management of feline au	1 0 7	11 15 (10–19) 3 (2–4)	14 16 (10- 3 (2-4		
Table 3 Efficacy of levetiracetam a	nd phenobarbital in the	Age at onset of seizures (years) Time from first seizure to study sta	diogenic refl	11 15 (10–19) 3 (2–4)	14 16 (10- 3 (2-4		0.1 1.C
Table 3 Efficacy of levetiracetam at Number of cats achieving ≥50% re- in the number of myoclonic seizure Mean percentage reduction from ba of myoclonic seizure days per week	duction from baseline days per week aseline in the number	Age at onset of seizures (years) Time from first seizure to study sta e management of feline au Levetiracetam group	diogenic refl Phenobar	11 15 (10–19) 3 (2–4) ex myoclonic s bital group	14 16 (10- 3 (2-4 seizures		

